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Objective: Preoperative use of clopidogrel increases the risk of bleeding, but its postoperative use has not
been studied. We studied early postoperative clopidogrel use in on-pump and off-pump coronary artery bypass
grafting.
Methods: Data were obtained from the University HealthSystem Consortium database. We conducted a retro-
spective analysis of data of 15,067 adults who had coronary artery bypass grafting between 2003 and 2006
and received perioperative aspirin alone or in combination with clopidogrel, with the latter administered within
2 days after coronary artery bypass grafting. Logistic regression was used to analyze in-hospital mortality, 30-day
readmission, ischemic or thrombotic events, and bleeding events, with propensity score adjustment for clopidog-
rel treatment.
Results: Combined aspirin and clopidogrel were used in 3268 patients (22%). Compared with aspirin alone,
aspirin plus clopidogrel was associated with reductions of in-hospital mortality (0.95% vs 1.78%; adjusted
odds ratio: 0.50; 95% confidence interval: 0.25, 0.99) and bleeding events (4.19% vs 5.17%; adjusted odds ratio:
0.70; 95% confidence interval: 0.51, 0.97). Ischemic or thrombotic events were not significantly different (1.29%
vs 1.53%; adjusted odds ratio, 0.99; 95% confidence interval: 0.59, 1.64). The relative effect of combined
treatment did not differ between on-pump and off-pump coronary artery bypass grafting.
Conclusions: Early postoperative clopidogrel combined with aspirin may be safe and beneficial compared with
perioperative aspirin treatment alone, in both on-pump and off-pump coronary artery bypass grafting. However,
a possibility of selection bias calls for randomized controlled trials to confirm our findings. (J Thorac Cardiovasc
Surg 2009;138:1377-84)
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MCoronary artery bypass grafting (CABG) without cardiopul-
monary bypass (‘‘off-pump’’) is associated with lower
short-term mortality and morbidity than CABG with cardio-
pulmonary bypass (‘‘on-pump’’),1,2 but concerns have been
raised about a potential prothrombotic state after off-pump
CABG.3-5 In addition, perioperative aspirin therapy im-
proves graft patency, prevents ischemic events, and prolongs
survival,6-8 although aspirin resistance is common after
CABG,9,10 in part due to cardiopulmonary bypass.11,12 To
improve outcomes after CABG, more aggressive antiplatelet
treatment with aspirin and clopidogrel may be warranted.
Data on the benefit and safety of clopidogrel use in pa-
tients having CABG mainly come from 2 randomized con-
trolled trials. In the Clopidogrel in Unstable angina to
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ministration of clopidogrel, along with aspirin, improved
cardiovascular outcomes in patients with non-ST segment
elevation acute coronary syndromes, including those pa-
tients having CABG.13,14 In this trial, clopidogrel was
stopped for a median of 10 days after CABG at the discretion
of the surgeons. A post hoc analysis suggested an increased
risk of bleeding associated with clopidogrel within 5 days
before CABG.14 The Clopidogrel Versus Aspirin in Patients
at Risk of Ischemic Events (CAPRIE) trial showed a long-
term benefit of clopidogrel compared with aspirin among pa-
tients who had cardiac surgery in the past.15 But these results
cannot be extrapolated to the perioperative period. In addi-
tion, clopidogrel alone may not provide effective platelet
inhibition in the early postoperative period.16
Thus, the optimal perioperative antiplatelet therapy remains
to be determined. Comparedwith preoperative use, the benefit
and safety of clopidogrel use in the early postoperative period
of CABG in addition to aspirin have been suggested in a few
small observational studies in off-pump CABG.17-20 Less
evidence exists on such therapy in on-pump CABG.20
Our study analyzed data collected from 52 academic med-
ical centers and affiliate hospitals in the United States during
a 4-year period (2003–2006). We hypothesized that, in pa-
tients having CABG, early postoperative administration ofrdiovascular Surgery c Volume 138, Number 6 1377
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MAbbreviations and Acronyms
AHRQ ¼Agency for Healthcare Research and
Quality
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
ICD-9-CM ¼ International Classification of
Diseases, 9th Edition, Clinical
Modification
OR ¼ odds ratio
UHC ¼ University HealthSystem Consortium
clopidogrel in addition to perioperative use of aspirin im-
proves short-term outcomes without significantly increasing
bleeding complications compared with aspirin alone. We
also explored whether the effect of such dual antiplatelet
therapy (vs aspirin alone) differs between on-pump and
off-pump CABG.
METHODS
Database and Study Design
The University HealthSystem Consortium (UHC) database is a clinical,
administrative, and financial database compiled from academic medical
centers and affiliate community hospitals to improve their clinical and oper-
ating efficiencies by pooling the data and providing benchmark measures.21
Data were extracted for the period between January 1, 2003, and December
31, 2006. Discharge abstracts were used to obtain sociodemographic char-
acteristics, admission source and status, 29 comorbidities defined by the
Agency for Healthcare Research and Quality (AHRQ),22 and postoperative
outcomes. All diagnoses and procedures were coded using the International
Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM).
Pharmacy records of when a medication was prescribed were used to deter-
mine medication use. Test results and details of procedures were not avail-
able in the UHC database. In addition, we included hospital-level
characteristics by linking to the American Hospital Association Guide.23
This was unfunded work; our analyses were approved by the Institutional
Review Board of Thomas Jefferson University, and informed consent was
waived.
Discharges were eligible if a patient was: (1) 18 years or older; (2) had
CABG, as captured by ICD-9-CM procedure codes 36.1X; and (3) had
received perioperative aspirin (at least 2 doses between 5 days before
and 2 days after CABG). Patients were excluded if clopidogrel was
started in the preoperative period (between 5 days before and 1 day before
CABG) or in the late postoperative period (later than 2 days after CABG).
Information on dosage of clopidogrel (with or without loading dose) was
not consistently available and therefore not included in the analysis. We
did not consider preoperative clopidogrel use, because patients who re-
quired it may differ significantly from those who did not, and because
it has already been shown to be associated with major bleeding
events.14,24-28 Similarly, we did not include late postoperative clopidogrel
use due to data limitations; the date of adverse events was not recorded in
the UHC database and therefore it would be impossible to determine
whether clopidogrel might have been started as a result of ischemic or
thrombotic events. Additional exclusion criteria were (1) hospitalization
longer than 1 week prior to CABG; (2) concomitant valvular procedure;
(3) warfarin use during the index hospitalization; and (4) missing or po-
tentially erroneous information on key variables. These criteria were used
to strengthen the homogeneity of the analysis sample and minimize con-
founding by case-mix.1378 The Journal of Thoracic and Cardiovascular SStudy Outcomes and Other Covariates
The primary study outcomewas in-hospital mortality.We also examined
30-day readmission rate, ischemic or thrombotic events (defined as postop-
erative acute myocardial infarction, stroke, and venous thromboembolism),
and any bleeding events (defined as postprocedural hemorrhage or hema-
toma and gastrointestinal hemorrhage). Diagnosis of each complication
was made retrospectively using the UHC Complication Profiler that uses
specific algorithms based on ICD-9-CM codes and diagnosis-related group
lists. We compared perioperative aspirin plus clopidogrel in the early post-
operative period versus perioperative aspirin alone on each of the above out-
comes, with adjustment for a number of patient and hospital characteristics.
We accounted for the following patient characteristics: age; sex; race;
primary payer; admission source and status; acute coronary syndrome (cap-
tured by ICD-9-CM diagnosis codes 410.X for acute myocardial infarction
and 411.1 and 411.8X for unstable angina); 29 AHRQ-defined comorbid-
ities (congestive heart failure, valvular disease, pulmonary circulation disor-
ders, peripheral vascular disorders, hypertension, paralysis, other
neurologic disorders, chronic pulmonary disease, diabetes with or without
chronic complications, hypothyroidism, renal failure, liver disease, chronic
peptic ulcer disease, HIV and AIDS, lymphoma, metastatic cancer, solid tu-
mor without metastasis, rheumatoid arthritis and collagen vascular diseases,
coagulation deficiency, obesity, weight loss, fluid and electrolyte disorders,
blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psycho-
ses, and depression)22; perioperative medication use (angiotensin convert-
ing enzyme inhibitors or angiotensin receptor blockers, beta-blockers,
calcium channel blockers, direct thrombin inhibitor, diuretics, heparin,
lipid-lowering agents, low-molecular-weight heparin, nonsteroidal anti-in-
flammatory drugs, and vasopressors or inotropes); type of CABG (on-
pump vs off-pump; captured by ICD-9-CM procedure code 39.61); and
number of bypass grafts. The All Patient Refined-Diagnosis Related Group
diagnosis code, severity of illness, and risk of mortality (3 M Health Infor-
mation Systems, Minneapolis, Minn)29 were also included, because they
have been shown to be a valid method of risk adjustment in CABG.30,31
We also accounted for the following hospital characteristics: hospital
CABG volume, proportion of off-pump CABG, number of beds, member-
ship in the Council of Teaching Hospitals, profit status, location (urban vs
rural), and geographical region. Hospital CABG volume, defined as the
number of CABG procedures performed at a hospital in a year (<100,
100–299, 300–499, and 500/y), and proportion of off-pump CABG
were treated as time-dependent variables. Geographical region was defined
according to the US census (Northeast, Midwest, South, and West).32
Statistical Analysis
We used logistic regression to compare aspirin plus clopidogrel versus
aspirin alone. Because the decision to use clopidogrel in addition to aspirin
is typically not made in a randommanner, the characteristics of patients who
receive both aspirin and clopidogrel are likely to differ from those of pa-
tients who receive aspirin alone. Due to the low event rates of most study
outcomes, it was not feasible to include all measured variables in amultivari-
able model. Therefore, we used the propensity score approach.33
In estimating the propensity score, we modeled the likelihood of receiv-
ing aspirin plus clopidogrel versus aspirin alone as a function of all covari-
ates. We started with a base model that included all the patient-level and
hospital-level covariates listed above, and then checked the addition of all
2-way interactions, one at a time. We fit a model with all main effects
plus any 2-way interactions significant at the 0.10 level in the previous
step. Finally, we conducted a stepwise backward elimination, retaining all
main effects, and all interactions significant at the 0.10 level. Based on
this final model, we estimated the propensity score for receiving aspirin
plus clopidogrel versus aspirin alone.
The main analyses consisted of a logistic regression model for each out-
come. Each model included treatment group, as well as the propensity score
(in 10 equal-size groups, ‘‘deciles’’).We also carried out 2 subgroup analyses
for each outcome. The first analysis examined the difference between the 2urgery c December 2009
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Mtreatment groups among on-pump and off-pump CABG and assessed the po-
tential interactionbetween treatment and on-pump/off-pumpCABG.The sec-
ond analysis was restricted to patients without acute coronary syndrome. To
account for the clustered nature of data (by hospital), the logistic regression
models used the Generalized Estimation Equations approach, with the robust
variance estimator. Propensity-adjusted odds ratios (ORs), 95% confidence
intervals (CIs), and P values were computed from the models. All analyses
were performed in Stata 9.2 (StataCorp, College Station, Tex).
RESULTS
Of a total of 20,093 adults who had CABG and received
perioperative aspirin between January 1, 2003, and Decem-
ber 31, 2006, 5026 were excluded based on prespecified cri-
teria, leaving a final analytical sample of 15,067 patients
(Figure 1). Patients had an average age (standard deviation)
of 64 (11) years, and three-quarters of them were men.
A total of 3268 (22%) patients received both aspirin and
clopidogrel. This fraction varied widely across the 52 differ-
ent hospitals represented in the data (median ¼ 10.7%; in-
terquartile range: 5.4%–38.3%) and was significantly
lower in government-owned hospitals (Table 1). Patients
who had peripheral vascular disease, received beta-blockers
and direct thrombin inhibitors, and had off-pump CABG
were also more likely to be treated with aspirin and clopi-
dogrel, whereas those with peptic ulcer were less likely
(Table 2). The median (interquartile range) for the estimated
propensity score was 72.6% (30.4%–95.1%) for the aspi-
rin-plus-clopidogrel group and 5.0% (1.5%–12.6%) for
the aspirin-alone group.
Main Analyses
Patients who received both aspirin and clopidogrel had
lower in-hospital mortality than those who received aspirin
alone (0.95% vs 1.78%, propensity-adjusted P ¼ .048,
Table 3). However, the 2 groups appeared similar with
Eligible Subjects Identified (N = 20,093)
(1) Age 18+ years
(2) CABG (ICD-9-CM 36.1X)
(3) Perioperative aspirin use
Subjects Excluded (N = 5,026)
(1) Preoperative and late postoperative clopidogrel use (n=2,506)
(2) Prolonged hospitalization (>1week) before surgery (n=153) 
(3) Concomitant valvular procedure (n=306)
(4) Warfarin use (n=2,031)
(5) Missing or erroneous information* (n=30)     
Subjects Included (N = 15,067)
- Aspirin alone (n=11,799)
- Aspirin and clopidogrel (n=3,268)
FIGURE 1. Selection of study sample. *Number of bypass grafts was un-
available for 8 cases. Procedure date preceded admission date in 22 subjects,
which was considered as erroneous information. CABG, Coronary artery
bypass grafting; ICD-9-CM, International Classification of Diseases, 9th
Edition, Clinical Modification.The Journal of Thoracic and Crespect to ischemic or thrombotic events (1.29% vs 1.53%,
P ¼ 0.960, Table 3), including acute myocardial infarction
(0.15% vs 0.11%), stroke (0.80% vs 0.82%), and venous
thromboembolism(0.37%vs0.61%).Becauseof the lowevent
rate, we cannot exclude a substantial benefit for either treat-
ment group (the aspirin-plus-clopidogrel group may be from
41% better up to 64% worse than the aspirin-alone group).
Surprisingly, bleeding events were also lower in the aspi-
rin-plus-clopidogrel group than in the aspirin-alone group
(4.19% vs 5.17%, P ¼ 0.029, Table 3). This difference
seemed to be mainly driven by the incidence of postproce-
dural hemorrhage or hematoma (3.82% vs 5.01%) but not
gastrointestinal hemorrhage (0.52% vs 0.50%).
Subgroup Analyses
The relative effect of aspirin and clopidogrel use versus
aspirin alone did not appear to differ significantly between
TABLE 1. Characteristics of hospitals with low versus high
clopidogrel use
Hospitals with
low aspirinþ
clopidogrel
use* (n ¼ 26)
Hospitals with
high aspirinþ
clopidogrel
use* (n ¼ 26) P
Aspirinþclopidogrel
use (%), median
(IQR)
5.4 (1.3, 8.3) 38.3 (26.1, 58.9) <.001
Off-pump CABG
(%), median
(IQR)
14.8 (7.2, 33.6) 25.3 (9.2, 42.4) .332
Hospital annual
CABG volume
(cases/y), median
(IQR)
143 (96, 237) 186 (120, 296) .194
Number of beds,
median (IQR)
505 (432, 686) 603 (476, 744) .103
Membership in the
Council
of Teaching
hospitals, n (%)
25 (96.2) 25 (96.2) 1.000
Profit status, n (%) .008
Profit 1 (3.9) 0 (0.0)
Nonprofit 7 (26.9) 18 (69.2)
Government 18 (69.2) 8 (30.8)
Location, n (%) 1.000
Urban 22 (84.6) 22 (84.6)
Rural 4 (15.4) 4 (15.4)
Geographical region,
n (%)
.471
South 8 (30.8) 9 (34.6)
Midwest 10 (38.4) 5 (19.2)
West 4 (15.4) 6 (23.1)
Northeast 4 (15.4) 6 (23.1)
IQR, Interquartile range;CABG, coronary artery bypass grafting. *Hospitals were clas-
sified via a split at the median of aspirin and clopidogrel use (10.7%); those with less
than 10.7% use were classified as ‘‘low use,’’ and those with 10.7% or higher were
classified as ‘‘high use.’’ardiovascular Surgery c Volume 138, Number 6 1379
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MTABLE 2. Selected patient characteristics and antiplatelet therapy
Aspirin alone
(n ¼ 11,799)
Aspirinþ
clopidogrel
(n ¼ 3,268) P
Age (y), n (%) .458
<60 4301 (36.4) 1198 (36.7)
60–69 3880 (32.9) 1064 (32.6)
70þ 3618 (30.7) 1003 (30.7)
Sex, n (%) .224
Male 8895 (75.5) 2439 (74.6)
Female 2874 (24.5) 829 (25.4)
Race, n (%) .177
White 8166 (69.2) 2449 (75.0)
Black 1149 (9.7) 298 (9.1)
Others 2484 (21.1) 521 (15.9)
Acute coronary
syndrome,* n (%)
2098 (17.8) 637 (19.5) .604
APR-DRG severity of illness, n (%) .235
Mild 1553 (13.2) 372 (11.4)
Moderate 5987 (50.7) 1636 (50.1)
Severe 3317 (28.1) 1007 (30.8)
Extreme 942 (8.0) 253 (7.7)
APR-DRG risk of mortality, n (%) .350
Mild 4496 (38.1) 1119 (34.2)
Moderate 4494 (38.1) 1276 (39.1)
Severe 2129 (18.0) 668 (20.4)
Extreme 680 (5.8) 205 (6.3)
Comorbidities, n (%)
Anemia 1485 (12.6) 395 (12.1) .644
Coagulopathy 778 (6.6) 201 (6.2) .518
Congestive heart failure 97 (0.8) 12 (0.4) .201
Diabetes mellitus 4619 (39.2) 1316 (40.3) .222
Hypertension 8343 (70.7) 2234 (68.4) .435
Peptic ulcer 60 (0.5) 7 (0.2) .004
Peripheral vascular disease 1482 (12.6) 477 (14.6) .004
Renal failure 826 (7.0) 251 (7.7) .587
Perioperative medication use, n (%)
ACE inhibitors or ARBs 6054 (51.3) 1673 (51.2) .570
Beta-blockers 11,286 (95.7) 3174 (97.1) .033
Calcium channel blockers 4487 (38.0) 1278 (39.1) .197
Direct thrombin inhibitors 138 (1.2) 46 (1.4) .001
Diuretics 11,459 (97.1) 2983 (91.3) .128
Heparin 10,563 (89.5) 3040 (93.0) .787
Lipid-lowering agents 9843 (83.4) 2727 (83.5) .055
Low-molecular-weight heparin 1903 (16.1) 487 (14.9) .070
NSAIDs 4228 (35.8) 1281 (39.2) .543
Vasopressors or inotropes 9879 (83.7) 2934 (89.8) .378
Cardiopulmonary bypass, n (%) .001
Off-pump CABG 2852 (24.2) 1567 (48.0)
On-pump CABG 8947 (75.8) 1701 (52.0)
Number of bypass grafts, n (%) .089
1 2811 (23.8) 840 (25.7)
2 4825 (40.9) 1298 (39.7)
3 3212 (27.2) 843 (25.8)
4þ 951 (8.1) 287 (8.8)
APR-DRG, All Patient Refined-Diagnosis Related Group; ACE, angiotensin convert-
ing enzyme; ARB, angiotensin receptor blocker; NSAID, nonsteroidal anti-inflamma-
tory drug; CABG, coronary artery bypass grafting. *Acute coronary syndrome
includes acute myocardial infarction and unstable angina.1380 The Journal of Thoracic and Cardiovascular Son-pump and off-pump CABG groups (Figure 2). Further-
more, the main results were similar when the analyses
were restricted to patients without acute coronary syndrome
(n¼ 12,332). The adjusted ORs (95% CIs) were 0.54 (0.30,
0.96) for in-hospital mortality, 0.83 (0.61, 1.12) for in-hos-
pital mortality or 30-day readmission, 1.11 (0.68, 1.81) for
ischemic or thrombotic events, and 0.64 (0.45, 0.91) for
bleeding events.
DISCUSSION
Unlike in the setting of percutaneous coronary interven-
tion,14,18 the role of combined aspirin and clopidogrel treat-
ment has not been well-defined in the setting of CABG.
Early postoperative administration of clopidogrel in addition
to aspirin has already been adopted by clinicians, but the im-
pact of such antiplatelet strategy has not been examined ex-
tensively. Given that preoperative aspirin and clopidogrel
treatment is associated with increased risk of bleeding com-
plications,14,24-28 we examined the benefit and safety of a dif-
ferent strategy of perioperative antiplatelet therapy. In a large
database of adult CABGpatients, we found that early postop-
erative clopidogrel administration in addition to periopera-
tive aspirin treatment was associated with a 50% relative
reduction of in-hospital mortality, compared with periopera-
tive aspirin treatment alone. This benefit was present after ad-
justment for patient-level and hospital-level characteristics
that affect the propensity to administer one type of treatment
or the other. The results did not differ significantly across the
use of cardiopulmonary bypass or when the analysis was lim-
ited to patients without acute coronary syndrome.
Benefit and Safety of Early Postoperative Clopidogrel
Use Combined with Aspirin
Our study supports previous reports that administration of
clopidogrel in the early postoperative period in addition to
aspirin may be potentially beneficial and safe following
off-pump CABG. Although preoperative aspirin and clopi-
dogrel treatment has been evaluated in several observational
studies,14,24-28 such therapy in the early postoperative period
has been examined only in a few small samples of patients
having off-pump CABG.17-20 These studies used predefined
protocols that administer clopidogrel several hours after
CABG andwhen chest tube drainage was reduced. In a retro-
spective analysis of 364 patients, Halkos and colleagues17
found that clopidogrel with an initial loading dose of 150
mg 4 hours postoperatively and a maintenance dose of 75
mg daily for 4 weeks (in addition to perioperative aspirin
treatment) were associated with lower in-hospital mortality.
In a prospective cohort study of 591 patients, Gurbuz and
associates19 reported that clopidogrel administration on the
first postoperative day without a loading dose for at least
30 days (in addition to aspirin) was associated with de-
creased adverse cardiac events and death, without an excess
of bleeding events. In a prospective cohort study of 117urgery c December 2009
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Aspirin alone (n ¼ 11,799) Aspirinþclopidogrel (n ¼ 3,268)
Unadjusted Estimated* Unadjusted Estimated* Propensity-Adjusted
Outcomes n rate rate n rate rate OR (95% CI) P
In-hospital mortality 210 1.78 1.59 31 0.95 0.81 0.50 (0.25, 0.99) .048
In-hospital mortality or 30-day
readmission
1004 8.51 9.59 265 8.11 7.87 0.81 (0.61, 1.06) .118
Ischemic/thrombotic events 180 1.53 1.26 42 1.29 1.25 0.99 (0.59, 1.64) .960
In-hospital mortality or
ischemic/thrombotic events
364 3.09 2.77 71 2.17 2.17 0.78 (0.47, 1.28) .322
Bleeding events 610 5.17 5.09 137 4.19 3.62 0.70 (0.51, 0.97) .029
CABG, Coronary artery bypass grafting;OR, odds ratio; CI, confidence interval. *Estimated rates were calculated from the fifth decile of propensity score for receiving aspirin plus
clopidogrel versus aspirin alone.P
Mpatients who had low chest tube drainage after on-pump and
off-pump CABG, Chan and coworkers20 found no differ-
ence in bleeding complications between aspirin 81 mg
plus clopidogrel 75 mg and aspirin 325 mg.20 Furthermore,
a case series of 135 patients suggested the safety of aspirin
and clopidogrel treatment when they were given 6 hours
after off-pump CABG.18 Our study provides additional
evidence of the short-term benefit and safety of early postop-
erative clopidogrel use combined with aspirin. Due to lack of
information on dose, our findings should be interpreted as
the effect of ‘‘typical’’ dose used in the real-world setting.
Several lines of evidence suggest that early administration
of clopidogrel in addition to aspirin after CABG may reduce
mortality and ischemic events. Aspirin and clopidogrel
have been shown to reduce cardiovascular death, myocardial
infarction, and stroke in patients with acute coronary syn-
drome14,34 as well as in patient with established atherothrom-
botic disease.15 Although the benefits of clopidogrel on
graft patency have not been examined, administration ofThe Journal of Thoracic and Cticlopidine in the early postoperative period was shown to
improve graft patency35 and similar efficacy in coronary
stenting has been reported between ticlopidine and clopidog-
rel.36 Experimental studies have shown that combined aspi-
rin and clopidogrel inhibit thrombogenesis in graft.37 In the
CURE trial, the benefits of clopidogrel started to emerge
within 24 hours of initiation of treatment.38 Because early
graft occlusion can occur as a result of platelet activation
from endothelial damage and inflammatory cell activation,
aspirin and clopidogrel treatment in the early postoperative
period may prevent graft occlusion. An ongoing randomized
controlled trial is evaluating the effects of early postoperative
clopidogrel and aspirin versus aspirin alone on saphenous
vein graft intimal hyperplasia following CABG.39
Benefit and Safety of Aspirin and Clopidogrel Use in
On-Pump and Off-Pump CABG
Our findings suggest that the benefit and safety of early
postoperative clopidogrel administration in addition to0.10 1.00 10.00
In-hospital mortality
On-pump              143 / 8,947        1.60        1.47            14 / 1,701        0.82        0.76
Off-pump               67 / 2,852        2.35        2.08            17 / 1,567        1.08        1.02
In-hospital mortality or 30-day readmission
On-pump              751 / 8,947        8.39        9.49             136 / 1,701        8.00        7.44
Off-pump             253 / 2,852        8.87      10.64          129 / 1,567        8.23        9.31
Any ischemic/thrombotic events
On-pump              122 / 8,947        1.36        1.16                23 / 1,701        1.35        1.41          
Off-pump               58 / 2,852        2.03        1.58            19 / 1,567        1.21        1.14
In-hospital mortality or any ischemic/thrombotic events
On-pump              251 / 8,947        2.81        2.59               35 / 1,701        2.06        2.20
Off-pump             113 / 2,852        3.96        3.43             36 / 1,567        2.30        2.37
Any bleeding events
On-pump              469 / 8,947        5.24        5.22                80 / 1,701        4.70        3.93
Off-pump             141 / 2,852        4.94        4.40               57 / 1,567        3.64        2.83
Aspirin Alone                        Aspirin + Clopidogrel
Unadjusted  Estimated*                        Unadjusted  Estimated* 
n / N                  (%)           (%)               n / N                 (%)           (%)
P for interaction
0.885
0.399
0.144
0.384
0.374
FIGURE 2. Study outcomes for patients having on-pump and off-pump coronary artery bypass grafting. *Estimated rates were calculated from the fifth
decile of propensity score for receiving aspirin plus clopidogrel versus aspirin alone.ardiovascular Surgery c Volume 138, Number 6 1381
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Maspirin exists in both on-pump and off-pump CABG.
Although off-pump CABG has become popular due to its
low short-term mortality and complication rates (especially
hemorrhagic complications),1,2 some studies have found
no differences in outcomes between on-pump and off-
pump CABG40 and a higher revascularization rate,41 due
to a potentially prothrombotic state after off-pump
CABG.3-5 For this reason, the benefit and risk of periopera-
tive antiplatelet therapy have been examined mainly in
off-pump CABG, and limited information is available for
on-pump CABG.20
However, it has been suggested that on-pump CABG
is associated with an initial reduction in platelet count and
subsequent enhanced regeneration of platelets that are not
acetylated by aspirin, thereby conveying transient resistance
to aspirin.11,12 Clinical significance and appropriate man-
agement of such aspirin resistance after on-pump CABG
remain to be elucidated.
In-hospital mortality was lower in our analysis sample
(1.5% for on-pump CABG and 1.9% for off-pump
CABG) than that in the entire UHC database (2.5% and
2.0%) or in the Society of Thoracic Surgeons National Adult
Cardiac Surgery Database (2.9% and 2.3%).42 This may be
explained by our exclusion of patients with higher risk of
mortality, such as thosewho had concomitant valvular proce-
dure, received preoperative clopidogrel, were treated with
warfarin, or did not receive any antiplatelet treatment at all.
The latter group, in particular, constituted two-thirds of the
UHC CABG patients and had a relatively higher mortality
(2.4%). In contrast to previous reports,1,2 mortality appeared
somewhat higher in off-pump CABG than in on-pump
CABG in our sample. This discrepancy can be explained
by the post hoc analysis showing that those who received
antiplatelet treatment following on-pump CABG had lower
risk of mortality than those who had on-pump CABG and
did not receive antiplatelet treatment (2.2% and 2.6%).
Study Limitations
Given that this is an observational cohort study in which
clopidogrel use was determined by a surgeon’s preference
without randomization, our findings should be viewed
with caution. The main concern is selection bias and residual
confounding due to unmeasured factors that may be associ-
ated with patient outcomes and also influence the choice of
treatment. Although we applied a propensity score analysis
to reduce imbalance between the 2 treatment groups, this
method cannot eliminate hidden bias due to unmeasured var-
iables. In the UHC database, several pertinent clinical vari-
ables were not available, including dose of clopidogrel
therapy (with or without loading dose), left ventricular sys-
tolic function, previous stents, transfusion requirement prior
to or during operation, procedural characteristics, and post-
operative chest tube output. Information on individual sur-
geon characteristics was also unavailable.1382 The Journal of Thoracic and Cardiovascular SIn our analyses, the observed reduction of in-hospital
mortality associated with aspirin and clopidogrel use in
both on-pump and off-pump CABG did not seem to be the
result of a reduction of ischemic or thrombotic event rates.
Most protocols used in prospective studies18-20 included ad-
ministration of clopidogrel 75 mg without a loading dose,
which may not be effective enough to prevent ischemic or
thrombotic events in the immediate postoperative period.
In addition, the date of ischemic or thrombotic events was
unavailable in the UHC database, and therefore we were un-
able to determine whether clopidogrel was administered as
a result of an ischemic or thrombotic event. It is possible
that clopidogrel was prescribed after an ischemic or throm-
botic event that occurred within 48 hours after surgery. If
this were a common occurrence, such misclassification
may explain the lack of effectiveness of combined treatment
(compared with aspirin alone) in preventing ischemic or
thrombotic events.
Another unexpected finding of our analyses was that
bleeding events were significantly less common in the aspi-
rin-plus-clopidogrel group than in the aspirin-alone group.
Despite our propensity score adjustment, it is possible that
unmeasured factors might have influenced surgeons to pre-
scribe clopidogrel to patients with lower perceived risk of
bleeding. In addition, if prescribing clopidogrel 75 mg with-
out a loading dose had been a common practice during study
period, the bleeding risk might have been underestimated.
Bleeding events were not adjudicated across the sites ac-
cording to standardized bleeding scales, so some misclassi-
fication has to be assumed. Furthermore, the actual cause of
death and significance of bleeding events (ie, minor versus
major) were not recorded in the UHC database. Therefore,
we could not determine whether clopidogrel administration
might have been delayed or not considered due to the signif-
icance of bleeding events. This might have possibly induced
an apparent protective effect of the aspirin-plus-clopidogrel
group (compared with aspirin alone) with respect to bleeding
events.
Finally, because the duration of antiplatelet therapy after
discharge, long-term mortality, and revascularization rates
were not reported in the UHC database, we could not inves-
tigate the optimal duration and long-term benefit and risk of
early postoperative clopidogrel use combined with aspirin.
Although Gurbuz and colleagues19 reported no difference
in adverse cardiac outcomes and mortality between short-
term users and long-term users of clopidogrel after off-
pump CABG, available evidence from the CURE13 and
CAPRIE15 trials suggest a long-term benefit of aspirin and
clopidogrel in patients who are having CABG or those
with a history of CABG.
CONCLUSIONS
In the absence of randomized controlled trials specifically
assessing the efficacy and safety of more aggressiveurgery c December 2009
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Mperioperative antiplatelet therapy in CABG, our study is the
largest observational study to date to examine the benefit and
safety of early postoperative clopidogrel administration in
combination with perioperative aspirin treatment, among
both on-pump and off-pump CABG. Given a significant in-
crease in bleeding complications associated with its preoper-
ative use, clopidogrel should be discontinued at least 5 days
prior to CABG, according to current guidelines.43,44 How-
ever, when administered in the early postoperative period
in addition to aspirin after postoperative bleeding complica-
tions are excluded, clopidogrel may be safe and beneficial
compared with perioperative aspirin treatment alone among
patients having on-pump and off-pump CABG. Due to lim-
itations of our observational retrospective analyses of UHC
data and the lack of detailed clinical information, our study
does not provide clinicians with the information that is nec-
essary to determine the risk-to-benefit ratio of early postop-
erative clopidogrel administration in individual patients.
Therefore, more robust evidence from randomized con-
trolled trials are much awaited.
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